Ublituximab Bests Teriflunomide for MS in Two Phase 3 Trials

Ublituximab is superior to teriflunomide in suppressing multiple sclerosis relapses and lesions on MRI, suggest findings from the phase 3 ULTIMATE I and II trials.

Related Keywords

Lawrence Steinman , Viela Bio , Genentech Roche , Patricia Coyle , Sanofi Genzyme , Glaxosmithkline , Stanford Calif University , Alkermes , Ms Comprehensive Care Center , Bristol Myers Squibb , Stony Brookny Neurosciences Institute , Novartis , New England Journal , Care Center , Stony Brook , Neurosciences Institute , Multiple Sclerosis Ms , Multiple Sclerosis , Us , Disability , Intravenous Iv , Intravenous , Tv , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Magnetic Resonance Imaging Mri , Magnetic Resonance Imaging , Ri , Maging Magnetic Resonance , Cancer , Alignant Neoplasia , Arcinoma , Fever , Headache , Hyperthermia , Heat Exhaustion , Heat Prostration , Opportunistic Infection ,